| Code | CSB-RA021334MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to ES-004, targeting Signal Regulatory Protein Alpha (SIRPA, also known as CD172a or SHPS-1). SIRPA is an inhibitory receptor expressed primarily on myeloid cells, including macrophages, dendritic cells, and neutrophils, where it plays a critical role in regulating innate immune responses. Upon binding to its ligand CD47, SIRPA transmits a "don't eat me" signal that inhibits phagocytosis, allowing cells to evade immune surveillance. This mechanism is frequently exploited by cancer cells that overexpress CD47, making the SIRPA-CD47 axis an important therapeutic target in immuno-oncology. Dysregulation of SIRPA signaling has been implicated in various malignancies, autoimmune disorders, and inflammatory conditions.
ES-004 is an Fc-engineered monoclonal antibody targeting the αV1 domain of SIRPA. It is currently in clinical Phase I/II and is being evaluated for its safety, tolerability and preliminary efficacy in the treatment of advanced solid tumors. This biosimilar antibody provides researchers with a reliable tool for studying SIRPA biology, exploring checkpoint blockade mechanisms, and developing novel therapeutic approaches targeting the innate immune system in oncology and immunology research.
There are currently no reviews for this product.